Screener
Viridian Therapeutics, Inc. VRDN Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $164,986 | $212,382 |
| Marketable securities | 816,544 | 662,270 |
| Other receivable | 75,000 | — |
| Prepaid expenses and other current assets | 24,740 | 19,581 |
| Total current assets | 1,081,270 | 894,233 |
| Property and equipment, net | 2,765 | 1,228 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s short-term investments?
- Viridian Therapeutics, Inc. (VRDN) reported short-term investments of $816.54M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s short-term investments changed year-over-year?
- Viridian Therapeutics, Inc.'s short-term investments increased by 83.1% year-over-year, from $446.03M to $816.54M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s short-term investments?
- Over 5 years (2020 to 2025), Viridian Therapeutics, Inc.'s short-term investments has grown at a 52.0% compound annual growth rate (CAGR), from $81.74M to $662.27M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Viridian Therapeutics, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude